• Users Online: 36
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 21  |  Issue : 1  |  Page : 4-11

A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics


1 Assistant Professor, Department of Psychiatry, Apollo Medical College, Chittoor, Andhra Pradesh, India
2 Professor, Department of Psychiatry, Apollo Medical College, Chittoor, Andhra Pradesh, India
3 Junior Resident, Department of Anaesthesia, Apollo Medical College, Chittoor, Andhra Pradesh, India
4 Assistant Professor, Department of Pharmacology, Apollo Medical College, Chittoor, Andhra Pradesh, India

Correspondence Address:
Dr. Dinesh Panati
14-296, New Kayinikattu Street, Opposite Vegetable Market, Chittoor - 517 001, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AMH.AMH_4_20

Rights and Permissions

Introduction: The prevalence of metabolic syndrome is more in patients with schizophrenia receiving first- and second-generation antipsychotics. Aim and Objectives: The aim is to study the prevalence of metabolic syndrome in patients with schizophrenia treated with first-generation and second-generation antipsychotics and to compare the prevalence between two generations. Materials and Methods: The study sample was obtained from the patients attending the outpatient clinic or admitted to the inpatient unit of the department of psychiatry at tertiary care unit. Patients with schizophrenia, 50 each on treatment with first- and second-generation antipsychotics for a minimum of 4 months were measured for fasting blood glucose, blood triglycerides, high-density lipoprotein, blood pressure, and waist circumference. Adult treatment panel diagnostic guidelines were used to diagnose metabolic syndrome. Results: The prevalence of metabolic syndrome in first-generation group was (18%) and second-generation group was (40%). Comparison of the prevalence between the two groups showed Mann–Whitney value of −2.412*, which was statistically significant at P < 0.05. There was significant difference found in the chlorpromazine equivalent dosage of antipsychotics at P < 0.001. It signifies that though the second-generation group had received lesser amount of antipsychotic dose when compared to first-generation group, the prevalence of metabolic syndrome was more in the second-generation antipsychotic group. Conclusion: Metabolic syndrome is seen in both the group of patients taking antipsychotics. In line with previous studies, our study also found that the prevalence of metabolic syndrome is more in patients taking second-generation antipsychotics.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1405    
    Printed71    
    Emailed0    
    PDF Downloaded128    
    Comments [Add]    

Recommend this journal